Hepatocellular carcinoma (HCC) is the most common primary malignancy of the liver. Angiogenesis is essential for solid tumors metastasis formation and growth and has been proven to play an important role in the progression of hepatocellular carcinoma. This survey would evaluate different aspects of this important issue.

by searching PUBMED and Scopus DATA base from 2012 to 2017.

Afferent and efferent vessels of HCC lesions come to differ as the lesion develops. Vascular endothelial growth factor (VEGF)/VEGF receptor (VEGFR) autocrine signaling is closely related to the growth, progression, and metastasis of HCC, making the VEGF/VEGFR axis an ideal target for the development of molecular targeted agents. Inhibition of VEGF signaling pathway has proven an effective strategy for the treatment of HCC patients. Anti-angiogenic therapy is the only approved systemic therapy for advanced hepatocellular carcinoma (HCC). Development of chemoresistance and relapse formation is observed in the majority of patients. Neo-angiogenesis is frequently observed during progression of hepatocellular carcinoma (HCC) and often associated with poor clinical outcome. Inhibition of neo-angiogenesis is an effective treatment strategy for advanced HCC.

Mechanism of Angiogenesis signaling and The Anti-angiogenic therapies offer an opportunity to increase our comprehension of this exceedingly complex pathway and could be an ideal potential target for treatment of Hepatocellular carcinoma.